NASDAQ:BIVI BioVie (BIVI) Stock Price, News & Analysis $3.18 -0.24 (-7.02%) (As of 10:46 AM ET) Add Compare Share Share Today's Range$3.17▼$3.4950-Day Range$0.29▼$3.8852-Week Range$2.07▼$58.20Volume38,089 shsAverage Volume147,196 shsMarket Capitalization$194.51 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get BioVie alerts: Email Address BioVie MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside17.0% Upside$4.00 Price TargetShort InterestHealthy1.42% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.65 out of 5 starsMedical Sector747th out of 924 stocksPharmaceutical Preparations Industry346th out of 426 stocks 2.3 Analyst's Opinion Consensus RatingBioVie has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBioVie has only been the subject of 1 research reports in the past 90 days.Read more about BioVie's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.42% of the float of BioVie has been sold short.Short Interest Ratio / Days to CoverBioVie has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioVie has recently decreased by 61.57%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioVie does not currently pay a dividend.Dividend GrowthBioVie does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BIVI. Previous Next 1.1 News and Social Media Coverage Search Interest4 people have searched for BIVI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows6 people have added BioVie to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioVie insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.50% of the stock of BioVie is held by insiders.Percentage Held by InstitutionsOnly 4.59% of the stock of BioVie is held by institutions.Read more about BioVie's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of BioVie is -3.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioVie is -3.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioVie has a P/B Ratio of 8.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Darwin2024's Must-Watch Stocks!Welcome to a year of unparalleled opportunities! Dive into our exclusive guide, "9 Stocks Set to Soar," meticulously selected to elevate your portfolio in 2024. Step into 2024 with confidence and the right assets at your fingertips. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time. [Unlock Your Report Now] About BioVie Stock (NASDAQ:BIVI)BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.Read More BIVI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIVI Stock News HeadlinesAugust 14, 2024 | markets.businessinsider.comBioVie to Present Overview of Bezisterim Clinical Data on Longevity at 11th Aging Research and Drug Discovery MeetingAugust 13, 2024 | americanbankingnews.comBioVie Inc. (NASDAQ:BIVI) Short Interest Down 61.6% in JulyAugust 22, 2024 | Behind the Markets (Ad)Secure this "AI Fuel" Stock Before the Billionaires Buy It AllAccording to the Washington Post, America is running out of a crucial component for AI. Without this "AI fuel," firms like NVIDIA would have to shut down their operations.August 8, 2024 | finanznachrichten.deBioVie, Inc.: BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson's DiseaseAugust 8, 2024 | finance.yahoo.comBioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson’s DiseaseAugust 8, 2024 | msn.comBioVie says FDA aligns with mid-stage Parkinson’s disease trialAugust 8, 2024 | globenewswire.comBioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson's DiseaseAugust 6, 2024 | globenewswire.comBioVie Inc. Announces Reverse Stock SplitAugust 22, 2024 | Behind the Markets (Ad)Secure this "AI Fuel" Stock Before the Billionaires Buy It AllAccording to the Washington Post, America is running out of a crucial component for AI. Without this "AI fuel," firms like NVIDIA would have to shut down their operations.August 6, 2024 | finance.yahoo.comIndividual investors invested in BioVie Inc. (NASDAQ:BIVI) copped the brunt of last week's US$55m market cap declineJune 20, 2024 | globenewswire.comBioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD CongressJune 12, 2024 | globenewswire.comJoin BioVie's Exclusive Live Investor Webinar and Q&A Session on June 26May 22, 2024 | finance.yahoo.comBioVie’s Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson’s Disease PatientsMay 22, 2024 | globenewswire.comBioVie's Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson's Disease PatientsMay 18, 2024 | nz.finance.yahoo.comBIVI Jul 2024 0.500 putMay 14, 2024 | finance.yahoo.comBioVie Inc. (BIVI)May 2, 2024 | stockhouse.comInvestors who Lost Money with BioVie Inc. (NASDAQ: BIVI) Shares Should Contact the Shareholders Foundation in Connection with Pending LawsuitApril 29, 2024 | proactiveinvestors.comBioVie secures $13.1M funding from US Department of Defense for Long COVID treatmentSee More Headlines Receive BIVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioVie and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today8/22/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BIVI CUSIPN/A CIK1580149 Webbioviepharma.com Phone(775) 888-3162FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$5.00 Low Stock Price Target$3.00 Potential Upside/Downside+17.0%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,260,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-294.42% Return on Assets-129.46% Debt Debt-to-Equity RatioN/A Current Ratio2.45 Quick Ratio2.45 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.42 per share Price / Book8.14Miscellaneous Outstanding Shares61,166,000Free Float57,802,000Market Cap$209.19 million OptionableOptionable Beta0.74 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Cuong Viet Do M.B.A. (Age 58)President, CEO & Director Comp: $1.08MMs. Joanne Wendy Kim CPA (Age 69)CFO, Treasurer & Corporate Secretary Comp: $397.38kDr. Joseph M. Palumbo M.D. (Age 64)Executive VP of R&D and Chief Medical Officer Comp: $722kMr. Clarence N. Ahlem (Age 69)Senior Vice President of Operations Dr. Penelope Markham Ph.D. (Age 58)Senior Vice President of Liver Disease Program Ms. Denise SmithSenior Vice President of Manufacturing & DevelopmentDr. Christopher L. Reading Ph.D. (Age 76)Senior Vice President of Alzheimer's Disease Program Ms. Sarah Overton Hoit (Age 56)Chief Social Impact Officer More ExecutivesKey CompetitorsCorvus PharmaceuticalsNASDAQ:CRVSTyme TechnologiesNASDAQ:TYMEAdamas PharmaceuticalsNASDAQ:ADMSEnlivex TherapeuticsNASDAQ:ENLVAytu BioPharmaNASDAQ:AYTUView All CompetitorsInsidersCuong V DoBought 10,000 shares on 11/30/2023Total: $17,800.00 ($1.78/share)Steve GorlinSold 8,560 sharesTotal: $26,108.00 ($3.05/share)Richard J BermanSold 10,805 sharesTotal: $37,817.50 ($3.50/share)View All Insider Transactions BIVI Stock Analysis - Frequently Asked Questions How have BIVI shares performed this year? BioVie's stock was trading at $1.26 on January 1st, 2024. Since then, BIVI shares have increased by 171.4% and is now trading at $3.42. View the best growth stocks for 2024 here. How do I buy shares of BioVie? Shares of BIVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BIVI) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
